



GIG  
CYMRU  
NHS  
WALES

Bwrdd Iechyd Prifysgol  
Bae Abertawe  
Swansea Bay University  
Health Board

Cadeirydd/Chair: **Emma Woollett**  
Prif Weithredwr/Chief Executive: **Mark Hackett**

**gofalu am ein gilydd, cydweithio, gwella bob amser**  
**caring for each other, working together, always improving**

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 4<sup>th</sup> March 2021  
Ein Cyf / Our Ref: 21-B-026

☎ 01639 648363

✉ FOIA.Requests@wales.nhs.uk

██████████  
██

Corporate Services  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

Dear ██████████

I refer to your Freedom of Information Act Request acknowledged by ourselves on 16<sup>th</sup> February 2021. Your request sought information relating to anti-VEGF treatments.

**1. For the 4-month period from September to December 2020, how many patients has your Health Board treated with the following anti-VEGF treatments:**

- **Aflibercept** - 1662
- **Bevacizumab** - 0
- **Brolucizumab** - 0
- **Dexamethasone** - 0
- **Fluocinolone acetonide** - 0
- **Ranibizumab** - 8

**2. Within your Health Board how many intra-vitreous injections/implants of each of the following treatments have been used in the four-month period from September to December 2020:**

- **Aflibercept** - 1707
- **Bevacizumab** - 0
- **Brolucizumab** - 0
- **Dexamethasone** - 50
- **Fluocinolone** - 0
- **Ranibizumab** - 11



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe  
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

**3. If your Health Board is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from September to December 2020 for each of the following conditions:**

**a. Wet Age Related Macular Degeneration (wAMD)**

- **Aflibercept** - 1531
- **Bevacizumab** - 0
- **Brolucizumab** - 0
- **Dexamethasone** - 0
- **Ranibizumab** - 11

**b. Diabetic Macular Oedema (DMO)**

Please note that we are not able to separate figures for DMO and CRVO/BRVO, therefore we have provided total numbers for all conditions below.

- **Aflibercept** - 176
- **Bevacizumab** - 0
- **Dexamethasone** - 50
- **Ranibizumab** - 0

**c. Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)**

Please see above.


- **Aflibercept**
- **Bevacizumab**
- **Dexamethasone**
- **Ranibizumab**

I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



On behalf of

---



Pam Wenger  
**Director of Corporate Governance**

